NCT03990571: Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

NCT03990571
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a metastatic adenoid cystic carcinoma
Exclusions: Patients with active untreated symptomatic central nervous system (CNS) involvement – see trial for details; Patients with prior treatment with immune checkpoint inhibitor (e.g. anti-PD-1/PD-L1) or VEGFR inhibitors (e.g. lenvatinib, bevacizumab)
https://ClinicalTrials.gov/show/NCT03990571

Comments are closed.

Up ↑